Ann: Positive clinical data filed with FDA to support ODD request, page-10

Maybe two ways of looking at it. The FDA may want to be seen to be acting promptly to progress promising treatments for MND in light of the flurry of bad news MND patients have just received. Remember, the ODD is not giving the green light to a drug but it is helping a company progress it to the next stage ASAP. The other way (less likely I hope) is that the FDA may want to be seen to be acting with more caution with potentially new treatments due to the failures on the recent "fast tracked" treatments.

My guess is the positive one, the FDA will want to be seen as acting in the best interests of the MND community and helping PAA get on track with progressing MPL Phase 2/3 ASAP. I'm guessing we hear back from them next month some time. i.e.mid/late April.